Intracranial arteritis is a well-known complication of cerebral cysticercosis. The aim of this study was to explore the possible role of transcranial Doppler (TCD) in the evaluation of cysticercotic arteritis in 9 patients with subarachnoid cysticercosis and stroke. Arteritis of main basal vessels was detected by TCD in 7 of 10 arterial lesions that were demonstrated by cerebral angiography. The Doppler pattern was occlusive in 2 cases and stenotic in 5. In the 3 patients with lacunar infarcts, both cerebral angiography and TCD were normal. In 6 arterial lesions followed serially with TCD a stenotic pattern resolved within 4 and 6 months in 3 cases and remained in the stenotic range at 12 months in 1 case, whereas an occlusive pattern persisted at 6 and 18 months in the other 2 cases. In conclusion, TCD may be useful to detect and follow up cerebral vasculitis due to chronic cysticercotic arachnoiditis.

1.
Centers for Disease Control and Prevention: Neurocysticercosis. Update: International Task Force for Disease Eradication. MMWR 1992;41:697–698.
2.
Barinagarrementeria F, Del Brutto OH: Lacunar syndrome due to neurocysticercosis. Arch Neurol 1989;46:415–417.
3.
Del Brutto OH: Cysticercosis and cerebrovascular disease: A review. J Neurol Neurosurg Psychiatry 1992;55:252–254.
4.
Alarcón F, Hidalgo F, Moncayo J, Viñan Y, Dueñas G: Cerebral cysticercosis and stroke. Stroke 1992;23:224–228.
5.
Barinagarrementeria F, Cantú C: Neurocysticercosis as a cause of stroke (letter). Stroke 1992;23:1180–1181.
6.
terPenning B, Litchman CD, Heier L: Bilateral middle cerebral artery occlusions in neurocysticercosis. Stroke 1992;23:280–283.
7.
Monteiro L, Almeida-Pinto J, Leite I, Xavier J, Correia M: Cerebral cysticercus arteristis: Five angiographic cases. Cerebrovasc Dis 1994;4:125–133.
8.
Levy AS, Lilleher KO, Rubenstein D, Stears JC: Subarachnoid neurocysticercosis with occlusion of the major intracranial arteries: Case report. Neurosurgery 1995;36:183–188.
9.
Soto-Hernández JL, Gómez-Llata AS, Rojas Echeverri LA, Texeira F, Romero V: Subarachnoid hemorrhage in neurocysticercosis. Neurosurgery 1996;38:197–200.
10.
Arnolds B, von Reutern GM: Transcranial Doppler sonography, examination technique and normal reference values. Ultrasound Med Biol 1986;12:115–123.
11.
Hennerici M, Rautemberg W, Sitzer G, Schwartz A: Transcranial Doppler ultrasound for the assessment of intracranial arterial flow velocity. Part I. Examination technique and normal values. Surg Neurol 1987;27:439–448.
12.
Babikian V, Sloan MA, Tegeler ChH, DeWitt LD, Fayad PB, Feldmann E, Gómez CR: Transcranial Doppler validation pilot study. J Neuroimaging 1993;3:242–248.
13.
Cantú C, Barinagarrementeria F: Cerebrovascular complications of neurocysticercosis: Clinical and neuroimaging spectrum. Arch Neurol 1996;53:233–239.
14.
Barinagarrementeria F, Cantú C: Cystercotic arteritis: Frequency in subarachnoid cysticercosis (abstract). Neurology 1996;46:A240.
15.
Bode H, Harders A: Transient stenosis and occlusions of main cerebral arteries in children: Diagnosis and control of therapy by transcranial Doppler sonography. Eur J Pediatr 1989;148:406–411.
16.
Haring HP, Rotzer HK, Reindl H, Berek K, Kampfl A, Pfausler B, Schmutzhard E: Time course of cerebral blood flow velocity in central nervous system infections. A transcranial Doppler sonography study. Arch Neurol 1993;50:98–101.
17.
Goh D, Minns RA: Cerebral blood flow velocity monitoring in pyogenic meningitis. Arch Dis Child 1993;68:111–119.
18.
Müller M, Merkelbach S, Huss GP, Schimrigk K: Clinical relevance and frequency of transient stenoses of the middle and anterior cerebral arteries in bacterial meningitis. Stroke 1995;26:1399–1403.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.